Jazz Pharmaceuticals plc announced that the Company and its partners will present 17 new abstracts from across its neuroscience portfolio at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 4-8, 2022.
“Our latest research being presented at SLEEP 2022 provides important insights that benefit people living with complex and severe sleep disorders, deepening our understanding of these debilitating conditions and their overarching effects on patients,” said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. “We continue to be pioneers in sleep medicine, building on the extensive data we’ve generated in narcolepsy and idiopathic hypersomnia. The breadth of data Jazz is presenting reinforces our passion for advancing research, elevating patient voices and addressing unmet needs through our transformational medicines.”
Highlights at SLEEP 2022 include:
- Two poster presentations sharing responder analyses from the Phase 3 idiopathic hypersomnia trial evaluating the efficacy and safety of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution as a treatment for adults with idiopathic hypersomnia.
- Interim data from both the TENOR and SEGUE studies in narcolepsy patients transitioning from sodium oxybate to lower-sodium Xywav.
- Results from two online surveys of U.S. patients and physicians providing meaningful perspectives on idiopathic hypersomnia, including the assessment of physician familiarity, symptoms, patient impact and disease management.
The SLEEP 2022 presentations and exhibit hall are available here.
Source: Jazz Pharmaceuticals
